Polymerase theta inhibition synergizes with anti-PD-1 immunotherapy in BRCA2-deficient pancreatic ductal adenocarcinoma.

被引：0

作者：

Patterson-Fortin, Jeffrey ^{[1
]}

Jadhav, Heta ^{[1
]}

Pantelidou, Constantia ^{[2
]}

Phan, Tin ^{[1
]}

Grochala, Carter ^{[1
]}

Hao, Jie ^{[1
]}

Wang, Junning ^{[1
]}

Andrews, Elizabeth A. ^{[1
]}

Guerriero, Jennifer L. ^{[3
]}

Wolpin, Brian M. ^{[1
]}

Stanger, Ben Z. ^{[4
]}

Aguirre, Andrew A. ^{[1
]}

Cleary, James M. ^{[1
]}

D'Andrea, Alan A. ^{[1
]}

Shapiro, Geoffrey I. ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Bayer US LLC, Pharmaceut, Boston, MA USA

[3] Brigham & Womens Hosp, Dept Surg, Div Breast Surg, 75 Francis St, Boston, MA 02115 USA

[4] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA

来源：

CANCER RESEARCH | 2022年 / 82卷 / 22期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

C010

引用

页码：117 / 118

页数：2

共 50 条

[21] Clinicopathological significance of mutations in BRCA1, BRCA2, and PALB2 in pancreatic ductal adenocarcinoma
Takeuchi, Shoko
Doi, Manami
Ikari, Naoki
Yamamoto, Masakazu
Furukawa, Toru
CANCER SCIENCE, 2018, 109 : 755 - 755
[22] BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma Discussion
Fleming, Jason
Vickers, Selwyn
Merchant, Nipun
Yeo, Charles J.
Brody, Jonathan
Lynn, Richard
He, Jin
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2018, 226 (04) : 637 - +
[23] Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma
Liu, Jing
Jiang, Wenna
Zhao, Kaili
Wang, Hongwei
Zhou, Tianxing
Bai, Weiwei
Wang, Xiuchao
Zhao, Tiansuo
Huang, Chongbiao
Gao, Song
Qin, Tai
Yu, Wenwen
Yang, Bo
Li, Xin
Fu, Danqi
Tan, Wei
Yang, Shengyu
Ren, He
Hao, Jihui
JOURNAL OF EXPERIMENTAL MEDICINE, 2019, 216 (03): : 656 - 673
[24] Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose) polymerase inhibition
Gallmeier, E
Kern, SE
CANCER BIOLOGY & THERAPY, 2005, 4 (07) : 703 - 706
[25] PSGL-1 deficiency eradicates orthotopic pancreatic ductal adenocarcinoma tumors in combination with anti-PD-1 therapy and enhances T cell anti-tumor immunity
Roy, Sreeja
Hope, Jennifer L.
Zhang, Yijuan
Palete, Ashley B.
Faso, Hannah A.
Otero, Dennis C.
Maganthi, Swetha
Commisso, Cosimo
Bradley, Linda M.
JOURNAL OF IMMUNOLOGY, 2023, 210 (01):
[26] High Nuclear Poly(Adenosine Diphosphate-Ribose) Polymerase Expression Is Predictive for BRCA1- and BRCA2-Deficient Breast Cancer Reply
Denkert, Carsten
Loibl, Sibylle
Mueller, Berit
von Minckwitz, Gunter
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (34) : 4588 - 4589
[27] PGAM1 suppression remodels the tumor microenvironment in triple-negative breast cancer and synergizes with anti-PD-1 immunotherapy
Zhang, Dong
Wang, Min
Wang, Wenying
Ma, Shiya
Yu, Wenwen
Ren, Xiubao
Sun, Qian
JOURNAL OF LEUKOCYTE BIOLOGY, 2024, 116 (03) : 579 - 588
[28] Brca1-deficient pancreatic ductal adenocarcinoma cells are hyper-sensitive to DNA-damaging agents
Hirsch, S.
Shakya, R.
Szabolcs, M.
Hartmann, J-T
Ludwig, T.
ONKOLOGIE, 2011, 34 : 57 - 57
[29] A Clinicopathologic and Molecular Study of BRCA1/2-mutated Pancreatic Ductal Adenocarcinoma
Li, Hongjie
Gibson, Joanna
Jain, Dhanpat
Finberg, Karin
Walther, Zenta
Zhong, Minghao
LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 1050 - 1051
[30] Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma
Seeber, Andreas
Zimmer, Kai
Kocher, Florian
Puccini, Alberto
Xiu, Joanne
Nabhan, Chadi
Elliott, Andrew
Goldberg, Richard M.
Grothey, Axel
Shields, Anthony F.
Battaglin, Francesca
El-Deiry, Wafik S.
Philip, Philip A.
Marshall, John L.
Hall, Michael
Korn, W. Michael
Lenz, Heinz-Josef
Wolf, Dominik
Feistritzer, Clemens
Spizzo, Gilbert
ESMO OPEN, 2020, 5 (06)

← 1 2 3 4 5 →